Bimzelx (bimekizumab-bkzx) Letter of Medical Necessity
Bimzelx (bimekizumab) is the first biologic that neutralizes both IL-17A and IL-17F. Payers commonly place it behind a preferred TNF inhibitor or IL-17A agent, so first-pass denials usually cite step therapy. A Letter of Medical Necessity that documents prior biologic failure and leverages the head-to-head trial data against adalimumab and secukinumab overturns most of them.
FDA-Approved Indications
- ● moderate-to-severe plaque psoriasis
- ● psoriatic arthritis
- ● non-radiographic axial spondyloarthritis
- ● ankylosing spondylitis
- ● moderate-to-severe hidradenitis suppurativa
Why Bimzelx Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: preferred TNF inhibitor or preferred IL-17A agent (Cosentyx, Taltz) not tried first
- 2. PASI, BSA, or IGA not documented at baseline
- 3. Phototherapy or conventional systemic trial not documented (psoriasis)
- 4. TB screening not on file
- 5. History of inflammatory bowel disease not addressed
- 6. Hurley stage and prior antibiotic trial not documented (HS)
What to Include in a Bimzelx Letter of Medical Necessity
Document the diagnosis with baseline severity (PASI, BSA, IGA for psoriasis; joint counts and BASDAI/ASDAS for PsA/axSpA; Hurley stage and abscess/nodule count for HS), prior conventional and biologic trials with dates, doses, and reasons for discontinuation, TB screening results, and IBD history. When requesting after an IL-17A failure, cite the dual IL-17A/F mechanism and BE RADIANT superiority data.
Key clinical evidence to cite:
- ✓ BE READY and BE VIVID Phase 3 trials (psoriasis) — high PASI 90 response vs placebo and ustekinumab
- ✓ BE SURE (head-to-head vs adalimumab) and BE RADIANT (head-to-head vs secukinumab) — superior PASI 100 response
- ✓ BE OPTIMAL and BE COMPLETE (psoriatic arthritis), BE MOBILE 1 and 2 (axial spondyloarthritis)
- ✓ BE HEARD I and II (hidradenitis suppurativa) — significant HiSCR response vs placebo
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
- 📖 ACR/SAA/SPARTAN 2019 Axial Spondyloarthritis Guidelines
- 📖 North American HS Clinical Management Guidelines
Bimzelx Prior Authorization Criteria
Standard criteria across major US payers for Bimzelx. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: preferred TNF inhibitor or preferred IL-17A agent (Cosentyx, Taltz) not tried first
- → Phototherapy or conventional systemic trial not documented (psoriasis)
- → Hurley stage and prior antibiotic trial not documented (HS)
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Bimzelx
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Bimzelx Prior Authorization FAQ
Why was my Bimzelx prior authorization denied?
The most common denial reasons for Bimzelx are: Step therapy: preferred TNF inhibitor or preferred IL-17A agent (Cosentyx, Taltz) not tried first; PASI, BSA, or IGA not documented at baseline; Phototherapy or conventional systemic trial not documented (psoriasis); TB screening not on file; History of inflammatory bowel disease not addressed; Hurley stage and prior antibiotic trial not documented (HS).
What should a Bimzelx Letter of Medical Necessity include?
Document the diagnosis with baseline severity (PASI, BSA, IGA for psoriasis; joint counts and BASDAI/ASDAS for PsA/axSpA; Hurley stage and abscess/nodule count for HS), prior conventional and biologic trials with dates, doses, and reasons for discontinuation, TB screening results, and IBD history. When requesting after an IL-17A failure, cite the dual IL-17A/F mechanism and BE RADIANT superiority data.
Which payers cover Bimzelx?
Bimzelx is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.